Table 1:

Demographic information for tumor cohort

	DART	EA1311	PERU	Entire Cohort
	n(%)	n(%)	n(%)	n(%)
Total	24	11	48	83
PAM50 Subtype
Basal	7 (29.17%)	4 (36.36%)	31 (64.58%)	42 (50.60%)
Her2 enriched	2 (8.33%)	3 (27.27%)	10 (20.83%)	15 (18.07%)
Luminal A	6 (25%)	1 (9.09%)	1 (2.08%)	8 (9.64%)
Luminal B	8 (33.33%)	3 (27.27%)	1 (2.08%)	12 (14.46%)
Normal	1 (4.17%)	0 (0%)	4 (8.33%)	5 (6.02%)
NA	0 (0%)	0 (0%)	1 (2.08%)	1 (1.20%)
IHC Subtype
ER+	20 (83.33%)	5 (45.45%)	1 (2.08%)	26 (31.33%)
PR+	13 (54.17%)	4 (36.36%)	1 (2.08%)	18 (21.69%)
HER2+	6 (25%)	2 (18.18%)	12 (25%)	20 (24.10%)
TNBC	4 (16.67%)	5 (45.45%)	35 (72.92%)	44 (53.01%)
Neoadjuvant Chemotherapy
TAXANE	21 (87.50%)	7 (63.64%)	21 (43.75%)	49 (59.04%)
NO TAXANE	3 (12.5%)	4 (36.36%	27 (56.25%)	34 (40.96%)